Avalo Therapeutics (AVTX) Competitors $3.79 -0.31 (-7.56%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$4.01 +0.22 (+5.70%) As of 05/21/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTX vs. MOLN, ELDN, OGI, INBX, PRQR, HURA, DMAC, ACIU, IKT, and ESPRShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Molecular Partners (MOLN), Eledon Pharmaceuticals (ELDN), Organigram (OGI), Inhibrx (INBX), ProQR Therapeutics (PRQR), TuHURA Biosciences (HURA), DiaMedica Therapeutics (DMAC), AC Immune (ACIU), Inhibikase Therapeutics (IKT), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Molecular Partners Eledon Pharmaceuticals Organigram Inhibrx ProQR Therapeutics TuHURA Biosciences DiaMedica Therapeutics AC Immune Inhibikase Therapeutics Esperion Therapeutics Avalo Therapeutics (NASDAQ:AVTX) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership. Do analysts rate AVTX or MOLN? Avalo Therapeutics presently has a consensus target price of $33.00, suggesting a potential upside of 770.71%. Molecular Partners has a consensus target price of $12.00, suggesting a potential upside of 203.03%. Given Avalo Therapeutics' higher probable upside, equities analysts clearly believe Avalo Therapeutics is more favorable than Molecular Partners.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Molecular Partners 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders & institutionals believe in AVTX or MOLN? 87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 26.5% of Molecular Partners shares are held by institutional investors. 3.0% of Avalo Therapeutics shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility and risk, AVTX or MOLN? Avalo Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Which has preferable valuation and earnings, AVTX or MOLN? Avalo Therapeutics has higher earnings, but lower revenue than Molecular Partners. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$441K93.06-$31.54MN/AN/AMolecular Partners$2.23M71.63-$69.04M-$1.92-2.06 Does the MarketBeat Community prefer AVTX or MOLN? Molecular Partners received 1 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 48.15% of users gave Molecular Partners an outperform vote while only 48.00% of users gave Avalo Therapeutics an outperform vote. CompanyUnderperformOutperformAvalo TherapeuticsOutperform Votes1248.00% Underperform Votes1352.00% Molecular PartnersOutperform Votes1348.15% Underperform Votes1451.85% Is AVTX or MOLN more profitable? Avalo Therapeutics has a net margin of 0.00% compared to Molecular Partners' net margin of -1,043.01%. Molecular Partners' return on equity of -39.31% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -442.16% 122.99% Molecular Partners -1,043.01%-39.31%-35.46% Does the media prefer AVTX or MOLN? In the previous week, Molecular Partners had 9 more articles in the media than Avalo Therapeutics. MarketBeat recorded 10 mentions for Molecular Partners and 1 mentions for Avalo Therapeutics. Molecular Partners' average media sentiment score of 0.43 beat Avalo Therapeutics' score of 0.00 indicating that Molecular Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Molecular Partners 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMolecular Partners beats Avalo Therapeutics on 10 of the 17 factors compared between the two stocks. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.04M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E RatioN/A8.9226.8419.71Price / Sales93.06253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.426.466.794.50Net Income-$31.54M$143.98M$3.23B$248.18M7 Day Performance5.28%3.04%4.07%1.14%1 Month Performance-14.06%7.44%12.52%15.20%1 Year Performance-65.29%-2.46%16.83%6.56% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics3.4076 of 5 stars$3.79-7.6%$33.00+770.7%-65.3%$41.04M$441,000.000.0040Gap DownMOLNMolecular Partners1.9444 of 5 stars$4.28+4.4%$12.00+180.4%+10.6%$172.81M$4.97M-1.99180Earnings ReportAnalyst RevisionELDNEledon Pharmaceuticals2.1569 of 5 stars$2.87-0.7%$12.50+335.5%+1.9%$171.86MN/A-1.4310News CoveragePositive NewsEarnings ReportAnalyst RevisionGap UpOGIOrganigram0.2575 of 5 stars$1.28+8.5%N/A-30.2%$171.31M$166.12M-3.37860Gap DownHigh Trading VolumeINBXInhibrx1.8939 of 5 stars$11.71+4.7%N/A-61.6%$169.51M$200,000.000.00166PRQRProQR Therapeutics3.1895 of 5 stars$1.59-1.2%$8.75+450.3%-9.5%$167.29M$18.91M-4.97180HURATuHURA BiosciencesN/A$3.82-4.3%$12.67+231.6%N/A$166.86MN/A0.00N/ANews CoverageEarnings ReportAnalyst RevisionDMACDiaMedica Therapeutics1.4867 of 5 stars$3.83+4.6%$8.00+108.9%+35.9%$164.14MN/A-6.8420News CoverageAnalyst RevisionGap UpACIUAC Immune2.732 of 5 stars$1.63-3.0%$10.00+513.5%-50.6%$163.67M$28.30M-3.54140Positive NewsGap UpIKTInhibikase Therapeutics1.5002 of 5 stars$2.19+9.5%$6.50+196.8%+4.2%$162.81M$260,000.00-0.826News CoverageGap DownESPREsperion Therapeutics3.5568 of 5 stars$0.80+0.1%$6.25+682.3%-64.6%$158.30M$259.57M-1.25200High Trading Volume Related Companies and Tools Related Companies Molecular Partners Competitors Eledon Pharmaceuticals Competitors Organigram Competitors Inhibrx Competitors ProQR Therapeutics Competitors TuHURA Biosciences Competitors DiaMedica Therapeutics Competitors AC Immune Competitors Inhibikase Therapeutics Competitors Esperion Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
